Samsung Peptide has successfully acquired a 97.99% stake in PolyPeptide Group AG through a public tender offer. This move signals the near-complete acquisition of the Swiss CDMO, with plans for a squeeze-out and delisting, significantly impacting PolyPeptide's future and Samsung Biologics' strategic expansion.
Samsung Peptide, a subsidiary of Samsung Biologics, has announced the definitive end result of its public tender offer for PolyPeptide Group AG, securing a 97.99% stake. This effectively means the acquisition is almost complete, pending regulatory approvals expected by late 2026 or early 2027. For PolyPeptide shareholders, this means an impending squeeze-out and delisting from the SIX Swiss Exchange, removing their ability to trade the stock publicly. For Samsung Biologics, this represents a significant strategic expansion into peptide and oligonucleotide API manufacturing, enhancing its CDMO capabilities. Short-term, PolyPeptide shareholders face the mandatory sale of their shares; long-term, Samsung Biologics strengthens its market position. The key risk for traders is the illiquidity and eventual delisting of PolyPeptide shares, while the opportunity lies in Samsung Biologics' enhanced growth prospects.